BACKGROUND: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. MATERIALS AND METHODS: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. RESULTS: A total of 30 patients were recruited. Median follow-up was 32 months (range: 8-48 months). Median age was 72 years (range: 70-84 years). The 3-year overall survival and local control were 93% and 80%, respectively. The median time to progression was 24 months (range: 6-30 months). Analyzing clinical outcome grouping based on the stage of disease, II versus III, the 3-year overall survival was 100% and 85%, respectively. The 3-year local control was 91% for stage II and 67% for stage III. Acute and late toxicities were acceptable without severe events. CONCLUSION: Weekly cisplatin and volumetric-modulated arc therapy-simultaneous integrated boost for radical treatment of advanced cervical cancer in the current cohort of elderly patients were feasible. Long-term results and prospective randomized trials are advocated.
BACKGROUND: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. MATERIALS AND METHODS: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. RESULTS: A total of 30 patients were recruited. Median follow-up was 32 months (range: 8-48 months). Median age was 72 years (range: 70-84 years). The 3-year overall survival and local control were 93% and 80%, respectively. The median time to progression was 24 months (range: 6-30 months). Analyzing clinical outcome grouping based on the stage of disease, II versus III, the 3-year overall survival was 100% and 85%, respectively. The 3-year local control was 91% for stage II and 67% for stage III. Acute and late toxicities were acceptable without severe events. CONCLUSION: Weekly cisplatin and volumetric-modulated arc therapy-simultaneous integrated boost for radical treatment of advanced cervical cancer in the current cohort of elderly patients were feasible. Long-term results and prospective randomized trials are advocated.
Authors: I Barillot; J C Horiot; J Pigneux; S Schraub; H Pourquier; N Daly; M Bolla; R Rozan Journal: Int J Radiat Oncol Biol Phys Date: 1997-07-15 Impact factor: 7.038
Authors: Sabrina T Heijkoop; Thomas R Langerak; Sandra Quint; Jan Willem M Mens; Andras G Zolnay; Ben J M Heijmen; Mischa S Hoogeman Journal: Radiother Oncol Date: 2015-09-22 Impact factor: 6.280
Authors: R Mazzola; S Fersino; A Fiorentino; F Ricchetti; N Giaj Levra; G Di Paola; G Sicignano; S Naccarato; R Ruggieri; F Alongi Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405
Authors: Giuseppe Facondo; Gianluca Vullo; Vitaliana DE Sanctis; Maurizio Valeriani; Anna Maria Ascolese; Maria Massaro; Dimitri Anzellini; Mattia Falchetto Osti Journal: Cancer Diagn Progn Date: 2021-05-03
Authors: Michelle B Rokni; Kelli B Pointer; Jonathan George; Jason J Luke; Steven J Chmura; Gage Redler Journal: J Appl Clin Med Phys Date: 2021-02-24 Impact factor: 2.102